MARKET

DARE

DARE

Dare Bioscience Inc
NASDAQ
0.2951
+0.0124
+4.39%
After Hours: 0.3100 +0.0149 +5.05% 19:59 04/18 EDT
OPEN
0.3086
PREV CLOSE
0.2827
HIGH
0.3109
LOW
0.2901
VOLUME
975.78K
TURNOVER
0
52 WEEK HIGH
1.100
52 WEEK LOW
0.2700
MARKET CAP
29.68M
P/E (TTM)
-0.8541
1D
5D
1M
3M
1Y
5Y
Dare Bioscience Cut to Hold From Buy by Brookline Capital
Dow Jones · 1d ago
Brookline Capital Downgrades Dare Bioscience to Hold
Benzinga · 1d ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
INVO Bioscience stock rose 275.0% to $2.85 during Wednesday's regular session. The company's Q4 earnings report came out yesterday. Vanda Pharma stock moved upwards by 33.33% during the session. Losers include Longeveron (NASDAQ:LGVN) and Dare BiosScience.
Benzinga · 1d ago
Weekly Report: what happened at DARE last week (0408-0412)?
Weekly Report · 3d ago
Daré Bioscience Announces Publication In Contraception Of Efficacy And Safety Findings From A Pre-Pivotal Postcoital Test Study Of Ovaprene: An Investigational Hormone-Free Monthly Intravaginal Contraceptive
Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women. Pivotal Phase 3 contraceptive efficacy clinical study of ovaprene currently enrolling has the potential to be first FDA-approved hormone-free monthly intravaginal contraceptive for women.
Benzinga · 04/11 12:15
Weekly Report: what happened at DARE last week (0401-0405)?
Weekly Report · 04/08 10:10
Analysts Are Bullish on These Healthcare Stocks: BiomX (PHGE), Daré Bioscience (DARE)
TipRanks · 04/03 18:50
Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Legend Biotech (LEGN) and Imunon (IMNN)
TipRanks · 04/01 10:20
More
About DARE
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.

Webull offers Dare Bioscience Inc stock information, including NASDAQ: DARE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DARE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DARE stock methods without spending real money on the virtual paper trading platform.